477 reports of this reaction
2.2% of all BUSPIRONE HYDROCHLORIDE reports
#8 most reported adverse reaction
DEPRESSION is the #8 most commonly reported adverse reaction for BUSPIRONE HYDROCHLORIDE, manufactured by Advagen Pharma Ltd. There are 477 FDA adverse event reports linking BUSPIRONE HYDROCHLORIDE to DEPRESSION. This represents approximately 2.2% of all 22,107 adverse event reports for this drug.
Patients taking BUSPIRONE HYDROCHLORIDE who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is a less commonly reported adverse event for BUSPIRONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to depression, the following adverse reactions have been reported for BUSPIRONE HYDROCHLORIDE:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 477 FDA reports for BUSPIRONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 2.2% of all adverse event reports for BUSPIRONE HYDROCHLORIDE, making it a notable side effect.
If you experience depression while taking BUSPIRONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.